UNH is under the spotlight after Berkshire Hathaway's 13F reveals it exited its entire stake, sparking surprise selling and fresh scrutiny on headwinds.
UnitedHealth $UNH Group Incorporated UNH is back in the spotlight after Berkshire Hathaway $BRK.B disclosed that it has sold its stake in the health insurer. The update came from Berkshire’s latest 13F filing, highlighted by Reuters, which showed the firm held no UNH shares as of March 31, 2026. UNH declined 2% from Thursday’s closing.
Berkshire is not a typical institutional holder. When it builds a position, investors often view it as a vote of confidence. Last August, Berkshire revealed that it had accumulated more than 5 million UNH shares as of June 30, 2025, a stake valued at roughly $1.57 billion. Buffett’s move was widely seen as a bet that the company’s setbacks at the time — including fallout from a major cyberattack, higher medical costs, softer earnings momentum and ongoing regulatory scrutiny — would ease over time. The disclosure helped lift sentiment and added fuel to UNH’s rebound.
The first quarter’s filing delivered the opposite reaction. The sudden exit caught traders off guard and added selling pressure to the stock, but many viewed the move as simple profit-taking or risk reduction rather than a sign that something was fundamentally wrong with the business. The UNH exit also fits into a wider portfolio shake-up under Berkshire’s new CEO, Greg Abel. The company trimmed or eliminated positions such as Amazon $AMZN, Visa $V and Mastercard $MA, while adding exposure to names like Delta Air Lines, Macy’s and Alphabet $GOOGL, pointing to a broader shift in positioning.
Meanwhile, several of the concerns Berkshire originally appeared willing to look past have not fully disappeared. Medical costs remain elevated (but better managed), Medicare Advantage margins are still tight, and regulatory questions continue to linger. UnitedHealth may be stabilizing, but the key headwinds are still in play.
Peers like Centene $CNC Corporation CNC and Elevance Health, Inc. ELV are also dealing with rising medical costs as utilization stays elevated. Still, both appear to be navigating the pressure. Centene’s health benefits ratio improved to 87.3% in the first quarter from 87.5% a year earlier, helped by stronger rates, higher revenues, better cost controls and milder flu-related costs. Elevance, however, saw its benefit expense ratio tick up to 86.8% from 86.4%, reflecting higher medical costs, partly offset by improved Medicare performance.
Shares of UNH have gained 18.5% in the year-to-date period compared with the industry’s growth of 17.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.42, up from the industry average of 17.32. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $18.25 per share, implying an 11.6% improvement from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
